ESMO Immuno-Oncology Congress 2019: Sponsor & Exhibitor Profiles

Who has already signed up?

ESMO gratefully acknowledge the valuable contribution the following organisations have made to the Immuno-Oncology Congress 2019. (As of September 2019):

Platinum Sponsor

Bristol-Myers Squibb

Bristol Myers Squibb Logo 2015

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.

Gold Sponsor

F. Hoffmann-La Roche Ltd

Roche logo

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. 

Bronze Sponsor

BD

BD-logo

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Supporters

Atara Biotherapeutics

Atara-Bio-logo

Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s pipeline includes tab-cel® (tabelecleucel), in clinical development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder as well as other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma.

IsoPlexis

IsoPlexis-Logo

IsoPlexis is dedicated to the fight against cancer and the world's toughest diseases with its award-winning single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, we advance immunotherapies and targeted therapies to a precise, personalized stage.  IsoPlexis systems advance the field of single-cell biology and biomarkers creating solutions to overcome the challenges of complex diseases.

NeoGenomics Laboratories

neogenomics logo

NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the U.S., and offer global capabilities with laboratories in Switzerland and Singapore.

Personalis, Inc.

Personalis-logo

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample.

Promega Corporation

promega-logo

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. Our Microsatellite Instability Analysis System (MSI) has been adopted as a gold standard for characterizing tumor tissue for MSI status, with over 120 peer-reviewed publications. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, cellular analysis, drug discovery.

Premium Educational Grant

Idera Pharmaceuticals, Inc.

Idera-logo

Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs).

Merck Pfizer Alliance

Merck Pfizer

Immuno-oncology is a top priority for Merck and Pfizer. The alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck. The alliance will jointly develop and commercialize avelumab and is striving to find new ways to treat cancer.